PF-Atlas › Clinical Trials › NCT01537666
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
AeroVanc · Phase 1
Registry ID
NCT01537666
Phase
Phase 1
Status
Completed
Drug / intervention
AeroVanc
Sponsor
Savara Inc.
Start
2011-11
About this trial
AeroVanc is evaluated in NCT01537666, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Savara Inc.. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01537666 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.